Drugs / BBio bOPV
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02766816 | Jun 2016 → Feb 2018 | — | Bilthoven Biologicals | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BBio bOPV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02766816 ↗ |
| Modality | Vaccine | “new bivalent oral polio vaccine (bOPV) containing World Health Organization (WHO) approved Sabin strains of poliovirus type 1 and type 3” NCT02766816 ↗ |
| Route | Oral | “orally” NCT02766816 ↗ |